What is new in iron overload?

European Journal of Pediatrics

Volumn 167, Issue 4, 2008, Pages 377-381

  Vermylen, Christiane ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Chelators; Diagnosis; Iron overload

Indexed keywords

AMINOTRANSFERASE; CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; HEMOSIDERIN; IRON;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; APLASTIC ANEMIA; ARTHRALGIA; BLOOD TRANSFUSION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; EYE TOXICITY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HUMAN; IRON OVERLOAD; IRON STORAGE; LIVER BIOPSY; LONG TERM EXPOSURE; MAGNETIC FIELD; MUSCULOSKELETAL PAIN; NAUSEA; NEUROTOXICITY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SIDE EFFECT; SUPERCONDUCTOR; TISSUE LEVEL; VOMITING; ZINC DEFICIENCY;

BIOPSY; CHILD; DIAGNOSIS, DIFFERENTIAL; FERRITINS; HUMANS; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX;

EID: 40049109580     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-007-0604-y     Document Type: Review

References (13)

1. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A (2006) Cardiac morbidity and mortality in deferoxamine or deferiprone-treated patients with thalassemia major. Blood 107:3733-3737
2. Cappellini MD (2005) Iron-chelating therapy with the new oral agent ICL670 (Exjade®). Best Pract Res Clin Haematol 18:289-298
3. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D (2006) A phase 3 study of deferasirox (ICL670), a once daily oral iron chelator, in patients with beta thalassemia. Blood 107:3455-3462
4. Cohen AR (2006) New advances in iron chelation therapy. http://www.asheducationbook.org Hematology 2006 42-47
5. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates T (2007) Cost effectiveness of once-daily oral chelation therapy with Deferasirox versus infusional Deferoxamine in transfusion-dependent thalassaemia patients. Pharmacoeconomics 25:329-342
6. Fischer R, Piga A, Harmatz P, Nielsen P (2005) Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci 1054:350-357
7. Glickstein H, Ben El R, Shvartsman M, Cabantchik I (2005) Intracellular labile iron pools as direct targets of iron chelators : a fluorescence study of chelator action in living cells. Blood 106:3242-3250
8. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, Perrin M, Jouanolle AM, Brissot P, Deugnier Y (2007) Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 46:587-595
9. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, drakaki K, Kaloumenou I, Galani A, Kattamis C (2006) Iron chelation treatment with combined therapy with deferiprone and deferioxamine : a 12-month trial. Blood Cell Mol Dis 36:21-25
10. Kontoghiorghes GJ (2006) New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert Opin Emerging Drugs 11:1-5
11. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107:3738-3744
12. Stumpf JL (2007) Deferasirox. Am J Health-Syst Pharm 64:606-616
13. Wood JC (2007) Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 14(3):183-190